| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Revenues: | |||||||||
Total revenues | |||||||||
51,165 | 41,372 | 26,774 | - | - | - | - | - | - | - |
Cost of sales | |||||||||
16,749 | 16,521 | 13,505 | - | - | - | - | - | - | - |
Product sales, net | |||||||||
- | - | - | 19,927 | 9,654 | 1,652 | 0 | - | - | - |
License revenues | |||||||||
- | - | - | 15 | 62 | 8 | 10 | 100 | 0 | - |
Total revenues | |||||||||
- | - | - | 19,942 | 9,716 | 1,660 | 10 | - | - | - |
Cost of sales | |||||||||
- | - | - | 9,831 | 5,206 | 1,093 | 0 | - | - | - |
Gross profit | |||||||||
34,416 | 24,851 | 13,269 | 10,111 | 4,510 | 567 | 10 | - | - | - |
Operating expenses: | |||||||||
Selling and marketing | |||||||||
- | - | - | 7,382 | 6,496 | 2,390 | 85 | - | - | - |
General and administrative | |||||||||
- | - | - | 17,569 | 12,504 | 8,087 | 5,994 | - | - | - |
Selling, general and administrative | |||||||||
33,096 | 29,243 | 25,019 | - | - | - | - | 2,980 | 827 | 2,307 |
Research and development | |||||||||
2,083 | 825 | 413 | 739 | 332 | 237 | 1,616 | 1,298 | 111 | 194 |
Impairment of long-lived assets | |||||||||
4,040 | - | - | - | - | - | - | - | - | - |
Total operating expenses | |||||||||
39,219 | 30,068 | 25,432 | - | - | - | - | - | - | - |
Impairment of long-lived assets | |||||||||
- | - | - | 303 | - | - | - | - | - | - |
Impairment of long-lived assets | |||||||||
- | - | - | - | 0 | - | - | - | - | - |
Total operating expenses | |||||||||
- | - | - | 25,993 | 19,332 | 10,714 | 7,696 | - | - | - |
Loss from operations | |||||||||
-4,803 | -5,217 | -12,163 | -15,882 | -14,822 | -10,147 | -7,686 | -4,178 | -939 | -2,502 |
Other income (expense): | |||||||||
Interest expense, net | |||||||||
-2,500 | -2,728 | -3,026 | -2,774 | -1,108 | 29 | - | - | - | - |
Loss on sale of assets | |||||||||
- | -393 | - | - | - | - | - | - | - | - |
Loss on sale of assets | |||||||||
- | - | -354 | - | - | - | - | - | - | - |
Interest expense | |||||||||
- | - | - | - | - | - | - | 24 | - | - |
Interest income | |||||||||
- | - | - | - | - | - | - | 15 | - | - |
Debt extinguishment loss | |||||||||
- | - | - | - | - | - | - | -1,195 | 0 | 26 |
Early extinguishment of debt | |||||||||
- | - | - | 1,966 | 0 | - | - | - | - | - |
Change in fair value of derivative liabilities | |||||||||
- | - | - | 113 | 0 | - | - | - | - | - |
Investment losses | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Gain on deconsolidation | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Loss on sale of assets | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Gain on settlement | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Gain on forgiveness of liabilities | |||||||||
- | - | - | - | - | - | - | 0 | - | - |
Gain on forgiveness of liabilities | |||||||||
- | - | - | - | - | - | - | - | 60 | - |
Other expense, net | |||||||||
- | - | - | - | - | - | - | 1,204 | 14 | 28 |
Other income (expense), net | |||||||||
630 | 103 | -884 | 1,537 | - | - | - | - | - | - |
Interest expense | |||||||||
- | - | - | - | - | - | 0 | - | 75 | 55 |
Interest income | |||||||||
- | - | - | - | - | - | 43 | - | 0 | 0 |
Total other (expense) income, net | |||||||||
4,678 | 19,842 | -757 | -3,316 | -1,077 | 29 | 43 | - | - | - |
(Loss) income before income taxes | |||||||||
-125 | 14,625 | -12,920 | -19,198 | - | - | - | - | - | - |
Other income, net | |||||||||
- | - | - | - | 31 | 0 | - | - | - | - |
Income tax benefit, net | |||||||||
- | - | -935 | -111 | 0 | - | - | - | - | - |
Total net (loss) income including noncontrolling interests | |||||||||
-125 | 14,625 | - | - | - | - | - | - | - | - |
Net loss attributable to noncontrolling interests | |||||||||
293 | - | - | - | - | - | - | - | - | - |
Net (loss) income attributable to Harrow Health, Inc. | |||||||||
168 | 14,625 | -11,985 | -19,087 | -15,899 | -10,118 | -7,643 | -5,383 | -953 | -2,531 |
Basic net (loss) income per share of common stock | |||||||||
0.01 | 0.67 | -0.60 | - | - | - | - | - | - | - |
Diluted net (loss) income per share of common stock | |||||||||
0.01 | 0.61 | -0.60 | - | - | - | - | - | - | - |
Weighted average number of shares of common stock outstanding, basic | |||||||||
25,323 | 21,917 | 20,027 | - | - | - | - | - | - | - |
Weighted average number of shares of common stock outstanding, diluted | |||||||||
26,466 | 23,812 | 20,027 | - | - | - | - | - | - | - |
Deemed dividend to preferred stockholders | |||||||||
- | - | - | - | - | - | - | 200 | 100 | 0 |
Net loss attributable to common stockholders | |||||||||
- | - | - | - | - | - | - | -5,583 | -1,053 | -2,531 |
Basic and diluted net loss per share of common stock | |||||||||
- | - | - | -1.50 | -1.66 | -1.11 | -0.88 | -1.24 | -2.65 | -0.16 |
Weighted average number of shares of common stock outstanding, basic and diluted | |||||||||
- | - | - | 12,743 | 9,576 | 9,132 | 8,656 | 4,493 | 397 | - |
Weighted average common shares outstanding, basic and diluted | |||||||||
- | - | - | - | - | - | - | - | - | 15,785 |
Sales, Net [Member] | |||||||||
Total revenues | |||||||||
51,137 | 41,334 | 26,684 | - | - | - | - | - | - | - |
License Revenues [Member] | |||||||||
Total revenues | |||||||||
28 | 38 | 90 | - | - | - | - | - | - | - |
Melt Pharmaceuticals [Member] | |||||||||
Investment (loss) gain, net | |||||||||
3,968 | - | - | - | - | - | - | - | - | - |
Surface Pharmaceuticals [Member] | |||||||||
Investment (loss) gain, net | |||||||||
-1,200 | 4,947 | - | - | - | - | - | - | - | - |
Eton Pharmaceuticals [Member] | |||||||||
Investment (loss) gain, net | |||||||||
3,780 | 17,913 | 3,507 | - | - | - | - | - | - | - |